![Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies](http://www.tropicalgastro.com/uploads/Untitlemscd-31.jpg)
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
![CA 19-9 tumor marker | pancreatic cancer diagnosis | tumor marker (Everything you need to know) - YouTube CA 19-9 tumor marker | pancreatic cancer diagnosis | tumor marker (Everything you need to know) - YouTube](https://i.ytimg.com/vi/eOWd34Q2NoM/maxresdefault.jpg)
CA 19-9 tumor marker | pancreatic cancer diagnosis | tumor marker (Everything you need to know) - YouTube
![Usefulness of CA 19–9 for pancreatic cancer screening in patients with new-onset diabetes - ScienceDirect Usefulness of CA 19–9 for pancreatic cancer screening in patients with new-onset diabetes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1499387218300900-gr4.jpg)
Usefulness of CA 19–9 for pancreatic cancer screening in patients with new-onset diabetes - ScienceDirect
![Median overall survival according to CA 19-9 serum level baseline level. | Download Scientific Diagram Median overall survival according to CA 19-9 serum level baseline level. | Download Scientific Diagram](https://www.researchgate.net/profile/Uwe-Pelzer/publication/240307282/figure/fig1/AS:216448275357696@1428616698105/Median-overall-survival-according-to-CA-19-9-serum-level-baseline-level_Q320.jpg)
Median overall survival according to CA 19-9 serum level baseline level. | Download Scientific Diagram
![The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma | BMC Cancer | Full Text The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-016-2897-6/MediaObjects/12885_2016_2897_Fig2_HTML.gif)
The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma | BMC Cancer | Full Text
![PDF] Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. | Semantic Scholar PDF] Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/66b1cd66c5a66439bb3847578e78918661a4df89/4-Table3-1.png)
PDF] Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. | Semantic Scholar
![Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer - HPB Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer - HPB](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9006c8c5-c7a3-4b79-885c-dd37d4c2a794/gr1.jpg)
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer - HPB
![Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. | Semantic Scholar Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9dd30be94b40d1a5584ba467f720202997d10fdb/4-Table1-1.png)
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. | Semantic Scholar
![Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies](http://www.tropicalgastro.com/uploads/Untitlnkged-30.jpg)
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
![CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2001025641/2003896921/gr1.gif)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
![Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1743919113010789-gr1.jpg)